Motus gi submits special 510(k) to fda for pure-vu evs gen 4 gastro and colon

– a special 510(k), according to fda guidance, is usually reviewed within 30 days of receipt – – pure-vu gen 4 platform opens up the upper gi market, reduces the cost-of-goods by approximately 50% and minimizes the need for onsite support to new accounts – fort lauderdale, fla., sept. 26, 2023 (globe newswire) -- motus gi holdings, inc., (nasdaq: mots) (“motus gi” or the “company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that it has submitted a special 510(k) to the u.s. food and drug administration ("fda") for market clearance of its pure-vu gen 4 gastro and colon.
MOTS Ratings Summary
MOTS Quant Ranking